0001209191-22-014661.txt : 20220302 0001209191-22-014661.hdr.sgml : 20220302 20220302160158 ACCESSION NUMBER: 0001209191-22-014661 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220228 FILED AS OF DATE: 20220302 DATE AS OF CHANGE: 20220302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Silver Ronald CENTRAL INDEX KEY: 0001873731 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34620 FILM NUMBER: 22703315 MAIL ADDRESS: STREET 1: 100 SUMMER STREET STREET 2: SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001446847 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043404176 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-621-7722 MAIL ADDRESS: STREET 1: 100 SUMMER STREET, SUITE 2300 CITY: BOSTON STATE: MA ZIP: 02110 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-28 0 0001446847 IRONWOOD PHARMACEUTICALS INC IRWD 0001873731 Silver Ronald C/O IRONWOOD PHARMACEUTICALS, INC. 100 SUMMER STREET, SUITE 2300 BOSTON MA 02110 0 1 0 0 Principal Accounting Officer Class A Common Stock 2022-02-28 4 S 0 448 10.77 D 63001 D Class A Common Stock 2022-02-28 4 S 0 640 10.77 D 62361 D Class A Common Stock 2022-02-28 4 S 0 1150 10.77 D 61211 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019. The reporting person acquired 2,236 shares of Class A Common Stock under the issuer's employee stock purchase plan on June 30, 2021. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2020. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 23, 2021. /s/ Brian Tessler, Attorney-in-Fact 2022-03-02